Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maria Stella, Maria Giuliani, Alessia Biolchi, Sara Tomei, Rosita De Paola, Xilian Bai, Ray Borrow, Jay Lucidarme, Rita La Gaetana, Daniela Toneatto, Mariagrazia Pizza, Laura Serino, Elena Mori, Marzia Monica Giuliani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2020-04-01
Edice:	Human Vaccines & Immunotherapeutics
Témata:	neisseria meningitidis meningococcus serogroup b meningococcal b vaccine 4cmenb meningococcal antigen typing system serum bactericidal antibody assay
On-line přístup:	http://dx.doi.org/10.1080/21645515.2019.1688039
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!